Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly and Company (LLY)'s share was trading at $868.88 as of Feb 10 th. LLY’s trailing and forward P/E were 74.20 and 38.17 respectively according to Yahoo Finance. 17 Most Drug Addicted Countries ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS) of $5.32 topped expectations of $5.11. Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra ... a new oral GLP-1 drug expected to compete directly with Novo’s Wegovy. In Q4 2024, Eli Lilly’s ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly, BCE ... Additional approvals like that and Lilly’s push to increase manufacturing should lead to ongoing, solid growth for the drugs, Edward Jones analyst John Boylan said in a ...